ResMed Inc. (RMD) Stock Analysis

ResMed’s competitive edge is anchored in its integrated ecosystem of devices, consumables, and cloud-based software, which creates high switching costs for both patients and providers. The company’s AirSense and AirCurve platforms, combined with proprietary software such as AirView and myAir, enable remote monitoring and drive patient adherence rates above 85%—notably higher than industry averages. This digital infrastructure is unmatched by primary rivals Philips Respironics and Fisher & Paykel Healthcare, who offer connected devices but lack ResMed’s scale in cloud-based patient management and data analytics.

Recurring revenue from mask and accessory resupply further strengthens ResMed’s position, as these consumables represent over a third of sales and are tied to ongoing therapy compliance. The company’s installed base exceeds 35 million cloud-connected devices, supporting a data lake of over 28 billion nights of sleep and respiratory data—an asset leveraged for AI-driven product improvements and patient engagement.

Brand trust and clinical credibility are reinforced by a robust pipeline and a history of peer-reviewed research, with over 1,000 publications. While Philips remains a formidable competitor, its recent recall has weakened its market share and reputation. ResMed’s scale, supply chain resilience, and focus on digital health position it to defend and expand its leadership, even as new entrants and alternative therapies (e.g., GLP-1 drugs, Inspire Medical) emerge.